» Articles » PMID: 24947265

Postradiation Imaging Changes in the CNS: How Can We Differentiate Between Treatment Effect and Disease Progression?

Overview
Journal Future Oncol
Specialty Oncology
Date 2014 Jun 21
PMID 24947265
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

A familiar challenge for neuroradiologists and neuro-oncologists is differentiating between radiation treatment effect and disease progression in the CNS. Both entities are characterized by an increase in contrast enhancement on MRI and present with similar clinical signs and symptoms that may occur either in close temporal proximity to the treatment or later in the disease course. When radiation-related imaging changes or clinical deterioration are mistaken for disease progression, patients may be subject to unnecessary surgery and/or a change from otherwise effective therapy. Similarly, when disease progression is mistaken for treatment effect, a potentially ineffective therapy may be continued in the face of progressive disease. Here we describe the three types of radiation injury to the brain based on the time to development of signs and symptoms--acute, subacute and late--and then review specific imaging changes after intensity-modulated radiation therapy, stereotactic radiosurgery and brachytherapy. We provide an overview of these phenomena in the treatment of a wide range of malignant and benign CNS illnesses. Finally, we review the published data regarding imaging techniques under investigation to address this well-known problem.

Citing Articles

The Clinical Application of Dynamic Contrast-Enhanced MRI in Canine Masses of Mesenchymal and Epithelial Origin: A Preliminary Case Series.

Cho C, Kim J, Eom K Vet Sci. 2024; 11(11).

PMID: 39591313 PMC: 11598959. DOI: 10.3390/vetsci11110539.


Multidisciplinary management strategies for recurrent brain metastasis after prior radiotherapy: An overview.

Kotecha R, La Rosa A, Brown P, Vogelbaum M, Navarria P, Bodensohn R Neuro Oncol. 2024; 27(3):597-615.

PMID: 39495010 PMC: 11889725. DOI: 10.1093/neuonc/noae220.


Enhancing the Understanding of Breast Vascularity Through Insights From Dynamic Contrast-Enhanced Magnetic Resonance Imaging: A Comprehensive Review.

Sachani P, Dhande R, Parihar P, Kasat P, Bedi G, Pradeep U Cureus. 2024; 16(9):e70226.

PMID: 39463566 PMC: 11512160. DOI: 10.7759/cureus.70226.


Are Dual-Phase F-Fluorodeoxyglucose PET-mpMRI Diagnostic Performances to Distinguish Brain Tumour Radionecrosis/Recurrence after Cranial Radiotherapy Usable in Routine?.

Cailleteau A, Ferrer L, Geffroy D, Fleury V, Lalire P, Dore M Cancers (Basel). 2024; 16(18).

PMID: 39335186 PMC: 11429908. DOI: 10.3390/cancers16183216.


Prospective Study to Evaluate the Role of Dual Point Contrast-enhanced Magnetic Resonance Imaging in Differentiation of Brain Tumoral from Nontumoral Tissue: A Magnetic Resonance/PET Study.

Mangalore S, Pradeep G, Murthy V, Bairwa P, Kumar P, Saini J Indian J Nucl Med. 2024; 39(2):87-97.

PMID: 38989312 PMC: 11232725. DOI: 10.4103/ijnm.ijnm_103_23.


References
1.
Hindo W, DeTrana 3rd F, Lee M, HENDRICKSON F . Large dose increment irradiation in treatment of cerebral metastases. Cancer. 1970; 26(1):138-41. DOI: 10.1002/1097-0142(197007)26:1<138::aid-cncr2820260117>3.0.co;2-5. View

2.
Macdonald D, Cascino T, Schold Jr S, Cairncross J . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7):1277-80. DOI: 10.1200/JCO.1990.8.7.1277. View

3.
Marks J, Baglan R, Prassad S, Blank W . Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys. 1981; 7(2):243-52. DOI: 10.1016/0360-3016(81)90443-0. View

4.
Kleinberg L, Yoon G, Weingart J, Parisi M, Olivi A, Detorie N . Imaging after GliaSite brachytherapy: prognostic MRI indicators of disease control and recurrence. Int J Radiat Oncol Biol Phys. 2009; 75(5):1385-91. DOI: 10.1016/j.ijrobp.2008.12.074. View

5.
Brandes A, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G . MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008; 26(13):2192-7. DOI: 10.1200/JCO.2007.14.8163. View